TY - JOUR
T1 - Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma
AU - Cruz, Carlos A.
AU - Rodriguez, Elizabeth R.
AU - Thawani, Maanvi
AU - Mazer, Margaret
AU - Hayhurst, Matthew
AU - Swanson, Madison
AU - Romero, Alexis
AU - Livingston, J. Andrew
AU - Aune, Greg
AU - Eshelman-Kent, Debra
AU - Cuglievan, Branko
AU - Roth, Michael E.
AU - Ahmed, Sairah
AU - Albritton, Karen
AU - Hildebrandt, Michelle A.T.
N1 - Publisher Copyright:
© 2025 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12–44). Patients who reported fevers and night sweats had shorter TTT than those who did not (p = 0.016 and p = 0.017, respectively). TTT varied significantly by age group (p < 0.01), with adolescents (15–18 years) having nearly a 10-day shorter TTT (21.3 days) compared to a TTT of 30.2 and 31.2 days for emerging adults (19–25 years) and young adults (26–39 years), respectively. Delayed TTT was not associated with risk of death. The lack of association with survival may reflect the overall favorable survival experienced by AYA HL patients and is in line with that reported for HL across all age populations.
AB - Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12–44). Patients who reported fevers and night sweats had shorter TTT than those who did not (p = 0.016 and p = 0.017, respectively). TTT varied significantly by age group (p < 0.01), with adolescents (15–18 years) having nearly a 10-day shorter TTT (21.3 days) compared to a TTT of 30.2 and 31.2 days for emerging adults (19–25 years) and young adults (26–39 years), respectively. Delayed TTT was not associated with risk of death. The lack of association with survival may reflect the overall favorable survival experienced by AYA HL patients and is in line with that reported for HL across all age populations.
KW - Hodgkin lymphoma
KW - adolescent and young adults
KW - time to treatment
UR - https://www.scopus.com/pages/publications/105004429777
UR - https://www.scopus.com/pages/publications/105004429777#tab=citedBy
U2 - 10.1080/10428194.2025.2499607
DO - 10.1080/10428194.2025.2499607
M3 - Article
C2 - 40337837
AN - SCOPUS:105004429777
SN - 1042-8194
VL - 66
SP - 1720
EP - 1726
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 9
ER -